Zhang Yi, Hua Xiaoliang, Shi Haoqiang, Zhang Li, Xiao Haibing, Liang Chaozhao
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, China.
Institute of Urology, Anhui Medical University, Hefei, Anhui, China.
Cancer Cell Int. 2021 Dec 19;21(1):680. doi: 10.1186/s12935-021-02364-2.
Eukaryotic initiation factor 3a (EIF3A), a "reader" protein for RNA methylation, has been found to be involved in promoting tumorigenesis in a variety of cancers. The impact of EIF3A in clear cell renal cell carcinoma (ccRCC) has yet to be reported. This study aimed to identify the prognostic value of EIF3A in ccRCC and investigate the relationship between EIF3A expression and immune infiltration.
We collected 29 m6A-related mRNA data and clinicopathological parameters from The Cancer Genome Atlas (TCGA) database. Logistic regression analyses were used to analyse the correlation between EIF3A expression and clinical characteristics. Immunohistochemistry (IHC) was applied to examine EIF3A levels in normal and ccRCC tissues. Univariate and multivariate analyses were conducted to recognize independent factors associated with overall survival (OS) and disease-free survival (DFS). The nomogram aimed to predict the 1-, 3- and 5-year survival probabilities. Gene set enrichment analysis (GSEA) was carried out to determine the potential functions and related signalling pathways of EIF3A expression. To investigate EIF3A of coexpressed genes, we used LinkedOmics, and the results were subjected to enrichment analysis. Simultaneously, LinkedOmics and STRING datasets were used to identify EIF3A coexpressed genes that were visualized via Cytoscape. Finally, we evaluated whether EIF3A expression correlated with the infiltration of immune cells and the expression of marker genes in ccRCC by Tumour Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA).
EIF3A expression was significantly different between ccRCC tissues and normal tissues. EIF3A expression was correlated with poor prognostic clinicopathological factors, and K-M analyses revealed that low EIF3A expression was correlated with a poor prognosis. The results of univariate and multivariate analyses proved that EIF3A was a prognostic factor in ccRCC patients. GSEA results indicated that EIF3A high expression was enriched in the renal cell carcinoma pathway. EIF3A expression was significantly positively correlated with B cells, CD8 + T cells, CD4 + T cells, neutrophils, macrophages, and dendritic cells. Furthermore, EIF3A expression was associated with most marker genes of immune cells.
EIF3A could serve as a potential biomarker for prognostic and diagnostic stratification of ccRCC and is related to immune cell infiltrates.
真核生物起始因子3a(EIF3A)是一种RNA甲基化的“读取”蛋白,已发现其参与多种癌症的肿瘤发生促进过程。EIF3A在透明细胞肾细胞癌(ccRCC)中的影响尚未见报道。本研究旨在确定EIF3A在ccRCC中的预后价值,并探讨EIF3A表达与免疫浸润之间的关系。
我们从癌症基因组图谱(TCGA)数据库收集了29个与m6A相关的mRNA数据和临床病理参数。采用逻辑回归分析来分析EIF3A表达与临床特征之间的相关性。应用免疫组织化学(IHC)检测正常组织和ccRCC组织中的EIF3A水平。进行单因素和多因素分析以识别与总生存期(OS)和无病生存期(DFS)相关的独立因素。列线图旨在预测1年、3年和5年生存概率。进行基因集富集分析(GSEA)以确定EIF3A表达的潜在功能和相关信号通路。为了研究共表达基因的EIF3A,我们使用了LinkedOmics,并对结果进行富集分析。同时,使用LinkedOmics和STRING数据集来识别通过Cytoscape可视化的EIF3A共表达基因。最后,我们通过肿瘤免疫评估资源(TIMER)和基因表达谱交互分析(GEPIA)评估EIF3A表达是否与ccRCC中免疫细胞的浸润和标记基因的表达相关。
ccRCC组织和正常组织之间EIF3A表达存在显著差异。EIF3A表达与不良预后的临床病理因素相关,Kaplan-Meier分析显示低EIF3A表达与不良预后相关。单因素和多因素分析结果证明EIF3A是ccRCC患者的一个预后因素。GSEA结果表明EIF3A高表达在肾细胞癌途径中富集。EIF3A表达与B细胞、CD8 + T细胞、CD4 + T细胞、中性粒细胞、巨噬细胞和树突状细胞显著正相关。此外,EIF3A表达与大多数免疫细胞标记基因相关。
EIF3A可作为ccRCC预后和诊断分层的潜在生物标志物,且与免疫细胞浸润相关。